Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development
Azrin N. Abd-Rahman, Sophie Zaloumis, James S. McCarthy, Julie A. Simpson, Robert J. Commons
Abstract
parasite reduction ratio over 48 h and parasite clearance half-life for Plasmodium falciparum following a single-dose monotherapy were 1.55 to 4.1 and 3.4 to 9.4 h, respectively. The antimalarial drug development landscape has seen a number of novel compounds, with promising PK-PD properties, evaluated in phase I and II studies over the past 5 years. Timely public disclosure of PK-PD data is crucial for informative decision-making and drug development strategy.
Topics & Concepts
Drug developmentDrugMedicinePharmacologyPlasmodium falciparumMalariaAntimalarial AgentDrug resistancePharmacodynamicsPharmacokineticsClinical trialPhases of clinical researchChloroquineCombination therapyDrug repositioningDrug interactionDrug discoveryIntensive care medicinePharmacotherapyClinical study designClinical researchMalaria Research and ControlPharmaceutical Quality and CounterfeitingParasitic Diseases Research and Treatment